Clinical Trial Update: Rapid P2Y12 Receptor Inhibition Attenuates Inflammatory Cell Infiltration in Thrombus Aspirated From the STEMI Patients [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating rapid P2Y12 receptor inhibition to reduce inflammatory cell infiltration in thrombus from STEMI patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammation
• St-segment Elevation Myocardial Infarction
• Thrombosis

Snippet

Sponsor: First Affiliated Hospital of Harbin Medical University | Conditions: Inflammation, Thrombosis | Phase 4 | Status: COMPLETED